Definiens AG To Present At The 23rd Molecular Medicine Tri-Conference
Dr. Ralf Huss to Discuss a Unique Approach Using Tissue Datafication in Cancer Research
MUNICH--(BUSINESS WIRE)--Definiens, the pioneer in Tissue Phenomics® solutions for diagnostics development and commercialization, today announced that chief medical officer Ralf Huss, a world renowned pathologist, will give a talk at the 23rd Molecular Medicine Tri-Conference, held in San Francisco, California from March 6th-11th. The company will also be exhibiting at Booth 423, presenting case studies and live demos.
“Integrated Phenomics and Big Data for Biomarker Discovery and Test Development”
Dr. Huss’ talk, entitled “Integrated Phenomics and Big Data for Biomarker Discovery and Test Development,” will discuss the discovery and use of tissue features to create quantitative assays for stratifying patients.
“The advantages to a Tissue Phenomics approach for tissue datafication and advanced mining are now well established, “ commented Huss. “For example, we have been working on a number of immune-oncology projects in which the only accurate way to correlate immune markers in the tumor with clinical outcomes is through our approach. I’m optimistic that the assays that come out of this work will have profound positive impact on future cancer patients.”
Dr. Huss’ presentation is part of the Digital Pathology Main Conference Program and takes place on Monday, March 7, 2016 from 4:25 – 4:40 p.m. PST.
Definiens is the pioneering provider of Tissue Phenomics® solutions for biomarker and companion diagnostics development and commercialization. Definiens’ technology empowers smarter tissue-based diagnostics by leveraging quantitative tissue readouts and other big data sources. By enabling the development of powerful and precise assays for patient stratification and clinical trial enrollment, Definiens aims to dramatically improve patient outcomes. Definiens' Tissue Phenomics approach was awarded the 2013 Frost and Sullivan Company of the Year Award for Global Tissue Diagnostics and Pathology Imaging. For more information, please visit:www.definiens.com.
Jonathan Moll, +1 212-398-9680